Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PCSK9 Inhibition and Risk of Diabetes: Should We Worry?
Stefano Carugo, Cesare R. Sirtori, Alberto Corsini, et al.
Current Atherosclerosis Reports (2022) Vol. 24, Iss. 12, pp. 995-1004
Open Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events
Emanuel Raschi, Manuela Casula, Arrigo F.G. Cicero, et al.
Pharmacology & Therapeutics (2023) Vol. 250, pp. 108507-108507
Open Access | Times Cited: 34
Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative Review
Nicola Ferri, Massimiliano Ruscica, Sergio Fazio, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 4, pp. 943-943
Open Access | Times Cited: 15
Targeting PCSK9 reduces cancer cell stemness and enhances antitumor immunity in head and neck cancer
Qi‐Chao Yang, Shuo Wang, Yuan‐Tong Liu, et al.
iScience (2023) Vol. 26, Iss. 6, pp. 106916-106916
Open Access | Times Cited: 14
Updates in Small Interfering RNA for the Treatment of Dyslipidemias
Stefano Carugo, Cesare R. Sirtori, Guido Gelpi, et al.
Current Atherosclerosis Reports (2023) Vol. 25, Iss. 11, pp. 805-817
Open Access | Times Cited: 12
The Pleiotropic Effects of Lipid-Modifying Interventions: Exploring Traditional and Emerging Hypolipidemic Therapies
Dimitris Kounatidis, Nikolaοs Tentolouris, Natalia G. Vallianou, et al.
Metabolites (2024) Vol. 14, Iss. 7, pp. 388-388
Open Access | Times Cited: 4
Evolocumab safety and efficacy in hypercholesteremia patients with or without diabetes: a retrospective real-world analysis
Sultan Ibrahim Alraddadi, Hind Almodaimegh, Abdullah Kharbosh, et al.
Diabetology & Metabolic Syndrome (2025) Vol. 17, Iss. 1
Open Access
Therapeutic PCSK9 targeting: Inside versus outside the hepatocyte?
Alberto Corsini, Henry N. Ginsberg, M. John Chapman
Pharmacology & Therapeutics (2025), pp. 108812-108812
Closed Access
The correlation between proprotein convertase subtilisin/kexin type 9 and adiponectin in the progression from prediabetes to type 2 diabetes mellitus
Jun-Xu Gu, Kun Wang, Aimin Zhang, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Proprotein convertase subtilisin/kexin type 9: a promising marker of cardiovascular risk in post-menopausal diabetic women in primary prevention
Michelangelo Rottura, María Antonietta Barbieri, Carmine Siniscalchi, et al.
Frontiers in Medicine (2025) Vol. 12
Open Access
Atorvastatin enhances LDL receptor-mediated LDL-C uptake and modulates PCSK9 protein expression in pancreatic β-cells
Zhiyan Zhang, Huadong Zheng, Lusha Zhang, et al.
Islets (2025) Vol. 17, Iss. 1
Open Access
Increase of PCSK9 expression in diabetes promotes VEGFR2 ubiquitination to inhibit endothelial function and skin wound healing
Jianjun Gao, Fang-Yuan Wu, Yujia Liu, et al.
Science China Life Sciences (2024)
Closed Access | Times Cited: 3
Pleiotropy of PCSK9: Functions in Extrahepatic Tissues
Yusuf Ziya Şener, Lâle Tokgözoğlu
Current Cardiology Reports (2023) Vol. 25, Iss. 9, pp. 979-985
Closed Access | Times Cited: 7
Update on clinical and experimental management of diabetic cardiomyopathy: addressing current and future therapy
Peter Galis, Linda Bartosova, Veronika Farkašová, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 2
PCSK9 Inhibitors: The Evolving Future
Bijay Mukesh Jeswani, Shubhangi Sharma, Sawai Singh Rathore, et al.
Health Science Reports (2024) Vol. 7, Iss. 11
Open Access | Times Cited: 2
Proteomics and Lipidomics to unveil the contribution of PCSK9 beyond cholesterol lowering: a narrative review
Erica Gianazza, Chiara Macchi, Cristina Banfi, et al.
Frontiers in Cardiovascular Medicine (2023) Vol. 10
Open Access | Times Cited: 5
Therapeutic adherence in patients treated with PCSK9i: focus on skin side effects
Beatrice Dal Pino, Francesco Sbrana
Acta Cardiologica (2024) Vol. 79, Iss. 5, pp. 625-626
Closed Access | Times Cited: 1
PCSK9 and Lipid Metabolism: Genetic Variants, Current Therapies, and Cardiovascular Outcomes
Daniela Grejtáková, Iveta Boronova, Jarmila Bernasovská, et al.
Cardiovascular Drugs and Therapy (2024)
Open Access | Times Cited: 1
Sex and statin-related genetic associations at the PCSK9 gene locus: results of genome-wide association meta-analysis
Janne Pott, Azin Kheirkhah, Jesper R. Gådin, et al.
Biology of Sex Differences (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Causal relationship between genetic proxies for calcium channel blockers and the risk of depression: a drug-target Mendelian randomization study
Chaoyi Ye, Tingjun Wang, Huajun Wang, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 1
Proprotein convertase subtilisin/kexin type 9 deficiency in extrahepatic tissues: emerging considerations
Fengyuan Lu, En Li, Xiaoyu Yang
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Genetic Associations of Lipids and Lipid-Modifying Drug Targets With Type 2 Diabetes in the Chinese Population
Jiawen Lu, Yang Liu, Zhenqian Wang, et al.
JACC Asia (2024) Vol. 4, Iss. 11, pp. 825-838
Open Access | Times Cited: 1
Genome-wide association study for circulating metabolites in 619,372 individuals
Ralf Tambets, Jaanika Kronberg, Adriaan van der Graaf, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
The association between circulatory, local pancreatic PCSK9 and type 2 diabetes mellitus: The effects of antidiabetic drugs on PCSK9
Fengyuan Lu, En Li, Xiaoyu Yang
Heliyon (2023) Vol. 9, Iss. 9, pp. e19371-e19371
Open Access | Times Cited: 3
PCSK9 Inhibitor Use and Outcomes Using Concomitant Lipid-Lowering Therapies in the Veterans Health Administration
Jessica Eloso, Asma Awad, Xinhua Zhao, et al.
American Journal of Medicine Open (2023) Vol. 9, pp. 100035-100035
Open Access | Times Cited: 2
Importance of Dyslipidaemia Treatment in Patients with Type 2 Diabetes Mellitus
Dominik Strikić, Andro Vujević, Dražen Perica, et al.
(2023)
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top